|
|
Article: Moffitt Cancer Center Signs Licensing Agreement with Frantz BioMarkers, LLC.
- Article from:
- Business Wire
- Article date:
- May 14, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Technology to Improve Accuracy of Ovarian Cancer Diagnosis
TAMPA, Fla. -- Moffitt Cancer Center and Frantz BioMarkers, LLC have signed a license agreement on phospholipid biomarkers of ovarian cancer. Frantz BioMarkers, which has been granted exclusive worldwide rights to Moffitt's interests in the biomarkers, will pay initiation, developmental milestone and license maintenance fees, and royalties on sales. Moffitt and Frantz BioMarkers will collaborate on ovarian cancer biomarker research, combining use of these licensed markers with lipid markers developed independently by Frantz BioMarkers.
Each year, 26,000 women in the United States are diagnosed ...